These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
184 related items for PubMed ID: 14616732
1. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Frank U, Mutter J, Schmidt-Eisenlohr E, Daschner FD. Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732 [Abstract] [Full Text] [Related]
5. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients. Casellas JM, Tomé G, Bantar C, Bertolini P, Blázquez N, Borda N, Couto E, Cudmani N, Guerrera J, Juárez MJ, López T, Littvik A, Méndez E, Notario R, Ponce G, Quinteros M, Salamone F, Sparo M, Sutich E, Vaylet S, Wolff L. Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972 [Abstract] [Full Text] [Related]
6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS. Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554 [Abstract] [Full Text] [Related]
8. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli. Kuo HY, Wang FD, Yen YF, Lin ML, Liu CY. New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669 [Abstract] [Full Text] [Related]
9. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China]. Wang H, Chen MJ, China Nosocomial Pathogens Resistance Surveillance Study Group. Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):385-90. PubMed ID: 12820914 [Abstract] [Full Text] [Related]
12. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M. J Int Med Res; 2013 Dec 10; 41(6):1830-7. PubMed ID: 24265334 [Abstract] [Full Text] [Related]